Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
327 studies found for:    Open Studies | "Myeloproliferative Disorders"
Show Display Options
Rank Status Study
21 Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention: Procedure: Stem cell transplantation
22 Recruiting Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoid Leukemia;   Myeloproliferative Disease;   Myelodysplastic Syndrome;   Chronic Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Interventions: Drug: ARM A Cyclophosphamide;   Drug: ARM B Calcineurin inhibitor and methotrexate
23 Recruiting Familial Myeloproliferative Disorders
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Idiopathic Myelofibrosis
24 Recruiting Preventing Stem Cell Transplant Complications With a Blood Separator Machine
Conditions: MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention: Device: Graft Manipulation (CD34+ Selection)
25 Recruiting PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
Conditions: Primary Myelofibrosis;   Myeloproliferative Disorders
Interventions: Procedure: Allogeneic hematopoietic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Drug: Ruxolitinib
26 Not yet recruiting Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal
Condition: Myeloproliferative Disorders
27 Recruiting PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Conditions: Myeloid Malignancies;   Acute Myelogenous Leukemia;   Chronic Myelogenous Leukemia;   Myeloproliferative Disorders;   Myelodysplastic Syndrome
Interventions: Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose);   Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
28 Recruiting MSC and HSC Coinfusion in Mismatched Minitransplants
Conditions: Leukemia, Myeloid, Acute;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelocytic, Chronic;   Myeloproliferative Disorders;   Myelodysplastic Syndromes;   Multiple Myeloma;   Leukemia, Lymphocytic, Chronic;   Hodgkin's Disease;   Lymphoma, Non-Hodgkin
Interventions: Biological: Mesenchymal stem cells;   Other: Isotonic solution
29 Recruiting Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Conditions: Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total body irradiation;   Drug: Sirolimus
30 Recruiting SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Conditions: Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Advanced Systemic Mastocytosis;   Advanced Symptomatic Primary Eosinophilic Disorder
Intervention: Drug: SL-401
31 Recruiting Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic-Myeloproliferative Diseases;   Hematological Malignancies;   B-cell Malignancy, Low-grade;   Myelodysplastic Syndrome With Low-grade Lesions;   IgG Monoclonal Gammopathy of Uncertain Significance;   Smoldering Multiple Myeloma;   Waldenstrom Macroglobulinemia
32 Recruiting Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Conditions: Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions: Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
33 Unknown  Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: azacitidine;   Drug: bortezomib
34 Unknown  Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
Conditions: Graft Versus Host Disease;   Infection;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: polymerase chain reaction;   Other: bronchoalveolar lavage;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Procedure: bronchoscopy;   Procedure: management of therapy complications
35 Not yet recruiting Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Biological: RNA sample of total leukocytes before start of treatment
36 Recruiting Study of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia
Condition: Leukemia
Intervention: Drug: Sotatercept
37 Recruiting Evaluation of Ruxolitinib And Azacytidine Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm
Condition: Leukemia
Interventions: Drug: Ruxolitinib (RUX);   Drug: Azacitidine (AZA);   Behavioral: Questionnaires
38 Recruiting 8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia;   Relapsed Adult Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia Arising From Previous Myeloproliferative Disorder
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: 8-chloro-adenosine
39 Recruiting SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)
Conditions: Leukemia;   Myeloproliferative Diseases
Interventions: Drug: SGI-110;   Procedure: Donor Lymphocyte Infusion
40 Recruiting Study of Nivolumab in Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Nivolumab;   Behavioral: Questionnaire;   Behavioral: Phone Call

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years